Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-relate⦠(NCT00996684) | Clinical Trial Compass
UnknownPhase 2
Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration
United States30 participantsStarted 2009-10
Plain-language summary
The purpose of this study is to determine whether microplasmin given by intravitreal injection is effective and safe for the treatment of wet age-related macular degeneration (AMD) in patients who have focal vitreomacular adhesion (VMA)
Who can participate
Age range50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female subjects aged 50 years or older
* Presence of focal vitreomacular adhesion as seen by OCT
* BCVA of 20/800 or better in non-study eye
* Presence of active choroidal neovascular membrane
* Written informed consent obtained from subject prior to inclusion in the trial
Exclusion Criteria:
* Subjects who have previously received microplasmin
* Subjects with any vitreous hemorrhage or any other vitreous opacification which precludes adequate examination or investigation of study eye
* Patient with uncontrolled glaucoma including IOP \>25 mm Hg
* Subjects who have had vitrectomy or retinal detachment or who are aphakic or highly myopic (\>8.0 D) in the study eye
* Subjects who are pregnant or of child-bearing potential not utilizing an acceptable form of contraception. Acceptable methods include intrauterine device, oral, implanted or injected contraceptives, and barrier methods with spermicide.
* Subjects who, in the Investigator's view, will not complete all visits and investigations
* Patient who have PDT or any intravitreal injection in the last 10 days. Patients who in the examiners opinion will need intravitreal injection in the next 10 days (apart from microplasmin).
* Patients who have participated in an investigational drug trial in the past 30 days.
What they're measuring
1
The primary outcome is the proportion of patients in whom there is release of vitreomacular traction as assessed by ultrasonography, optical coherence tomography and physical examination